US-based medical device company Neural Analytics has launched its Lucid M1 Transcranial Doppler Ultrasound System.
The company has also pledged support to the Society of Vascular and Interventional Neurology's (SVIN) Mission 2020, a mission to improve stroke care by significantly increasing stroke treatments for eligible patients and reducing global stroke disability.
Neural Analytics co-founder and chief scientific officer Robert Hamilton said: “We are pleased to support SVIN on this important initiative to improve stroke treatment worldwide and help reduce the disability associated with this condition.
“A critical component for effective stroke treatment is determining an accurate diagnosis as quickly as possible in settings inside and outside the hospital.
"Neural Analytics is developing new and improved portable tools to help expedite the determination and treatment of patients suffering from these brain diseases.”
Cleared by the US Food and Drug Administration (FDA), the Lucid system is a portable brain monitoring system to measure cerebral blood flow velocities within the head and neck.
The system uses a type of ultrasound called Trans Cranial Doppler to non-invasively analyse the brain’s blood vessels from outside the body.
The non-invasive analysis can be performed in the physician’s office, and enables diagnosis of brain disorders, without the need for additional, more invasive tests.
The Lucid system is operated by a battery and has been designed as a medical grade tablet that can be easily moved in a range of settings that require the rapid assessment of blood flow in the brain to accelerate treatment.
Image: Lucid M1 Transcranial Doppler Ultrasound System. Photo: courtesy of Business Wire.